Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD180-ADC
- Development stage
- Preclinical
- Lead developer
- Corellia AI
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD180-ADC is an antibody-drug conjugate (ADC) designed to target CD180 (also known as RP105), a type I single-pass transmembrane protein that is highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells. Developed by Corellia AI and Champions Oncology, the agent consists of a fully human monoclonal antibody specific for the CD180/MD-1 complex, conjugated to a topoisomerase I inhibitor payload with a drug-to-antibody ratio (DAR) of 8. Upon binding to CD180, the ADC is rapidly internalized, releasing the cytotoxic payload to inhibit topoisomerase I, leading to DNA damage and apoptosis in malignant cells. Preclinical data presented at AACR 2026 demonstrated potent cytotoxicity across AML models and a favorable safety profile in non-human primates, supporting its advancement into clinical trials.
- Other names
- CD180-targeting ADCCD-180-targeting ADCCD 180-targeting ADC
02
Targets
CD180 (CD180 molecule)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on CD180-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD180-ADC.